(Q37717305)

22 August 2017

1 reference

title

Strategies and controversies in the treatment of gout and hyperuricaemia (English)

1 reference

22 August 2017

Fam AG

1

1 reference

22 August 2017

language of work or name

1 reference

1 August 1990

1 reference

Bailliere's clinical rheumatology

22 August 2017

published in

1 reference

22 August 2017

volume

4

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

177-192

1 reference

22 August 2017

cites work

Gout and hyperuricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Does colchicine work? The results of the first controlled study in acute gout.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Plasma oxipurinol concentrations during allopurinol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Renal outcomes of gout and hyperuricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Is it mandatory to examine synovial fluids promptly after arthrocentesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Colchicine myopathy and neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Asymptomatic Hyperuricemia: The Case for Conservative Management

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Allergic Reaction to Allopurinol with Cross-Reactivity to Oxypurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Withdrawal of allopurinol in patients with gout

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Long-term colchicine administration leading to colchicine toxicity and death

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

The Physiologic Approach to Hyperuricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Colchicine in acute gout. Reassessment of risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Hyperuricemia and gout. Classification, complications and management

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Long term uricosuric therapy in gout

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

Treatment of Acute Gout with Naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980016-0

7 January 2021

10.1016/S0950-3579(05)80016-0

Identifiers

DOI

1 reference

22 August 2017

1 reference